CATEGORIES: Featured | Research

Become a Certified CMT-FOM Clinical Evaluator at the HNF Clinical Trial Readiness Summit

by | Feb 27, 2025 | 0 comments

Become a Certified CMT-FOM Clinical Evaluator at the HNF Clinical Trial Readiness Summit

The Hereditary Neuropathy Foundation (HNF) is proud to offer an exclusive opportunity to become one of the first Fully Certified CMT-FOM Clinical Evaluators at the upcoming HNF Clinical Trial Readiness Summit in Nashville, TN. This groundbreaking training will take place from April 23-26, 2025.

This is a unique and FREE training opportunity led by Dr. Joshua Burns, PhD, at St. Jude Children’s Research Hospital and Dr. Kayla Cornett, PhD, at the University of Sydney designed for clinical professionals seeking to enhance their expertise in the Charcot-Marie-Tooth disease (CMT) Functional Outcome Measure (CMT-FOM). However, participants must cover their own travel expenses to Nashville.

Why Get Fully Certified?

Upon successful completion of this program, participants will receive Full Certification, granting them:

  • Membership of the inaugural group of Certified CMT Clinical Evaluators, listed on ClinicalOutcomeMeasures.org
  • Access to ongoing training, quality assurance, and advanced online knowledge resources
  • Exclusive Q&A sessions with Master Trainers
  • Eligibility to become a Master Trainer
  • Inclusion in a global community of practice with fellow Clinical Evaluators
  • Limited Spots Available – Register ASAP!

Limited Spots Available – Register ASAP!

Space is limited, so interested candidates should register as soon as possible to secure their spot.

For more information or to register, contact us at [email protected]

Why is CMT Clinical Training More Important Than Ever?

The landscape of CMT research and clinical trials is evolving rapidly, with new therapeutic approaches emerging and more clinical trials than ever before. The ability to accurately assess functional outcomes in individuals with CMT is critical to the success of these trials. With the growing adoption of wearable technologies, digital biomarkers, and advanced clinical measures, properly trained evaluators are in high demand to ensure the reliability of trial data. By becoming fully certified, clinical professionals will be equipped with the latest skills and expertise needed to drive forward groundbreaking treatments and accelerate the pathway to a cure.

Learn more on this topic

Related Blog Posts

Sneak Peak of Fall Newsletter: CMT Research Study Survey

by | Sep 16, 2014 | , | 2 Comments

My name is Elizabeth Francisco and I am a graduate student from the Genetic Counseling program at the University of North Carolina Greensboro. I am inviting you to participate in a research study. The goal of my study is to learn more about the experiences of people with Charcot-Marie-Tooth (CMT) with genetic counseling and genetic testing. Adults with CMT and parents or legal guardians of someone of any age who has a diagnosis of CMT are eligible to participate

Building Awareness on CMT and Supporting the Patient Community – HNF Announces Support from Pharnext

by | Aug 19, 2014 | , , | 1 Comment

HNFpharnext recently entered into a partnership with the French biopharmaceutical company, Pharnext, to help raise awareness of Charcot-Marie-Tooth (CMT) disease and support the CMT patient community through several initiatives. Building awareness is key! Pharnext’s support will assist HNF in distributing HNF’s CMT Update quarterly newsletter, enhancing the Global Registry for Inherited Neuropathies (GRIN), setting up activities for CMT September Awareness Month in the US and strengthening the CMT Inspire Community.

Quality of Life and CMT Research

by | Jul 7, 2014 | | 4 Comments

Did you know that 95% of clinical trials fail? There are multiple causes, most related to efficacy or safety, which obviously can be harmful and risky for patients. The risk-reward of enrolling in trials is a judgment call based on the devastating effects of disease related to quality of life (QoL) or life-threatening disease. With CMT, the risk-reward is more of a challenging question for many, as CMT in most cases is non-fatal.

Help us answer questions that your doctors and the CMT Research Community aren’t too sure about.

by | May 19, 2014 | | 0 Comments

Did you know that you can become part of a community in therapy development and further research for all forms of CMT and inherited neuropathies? The mission of the Global Registry for Inherited neuropathies (GRIN) is to collect clinical and genetic information from patients with ALL forms of Charcot-Marie-Tooth (CMT) and other related rare and ultra rare inherited neuropathies.

Hot off the press

by | Feb 28, 2014 | | 0 Comments

It seems like almost weekly there is another new publication on CMT with interesting basic biology. While an earlier “Hot off the press” highlighted the work of Cherry and co-workers at the University of Texas Southwestern Medical Center who showed show that neurons lacking a gene for rab7 result in neuropathy.

New Study on CMT Type 2B

by | Feb 12, 2014 | | 6 Comments

If we are to learn more about CMT and the effectiveness of rehabilitation it is worth asking the patient and their caregiver. A recent Italian study by Padua et al recently described a survey of CMT patients and caregivers and their perspectives and perceptions of rehabilitation efficacy and needs.

Allison Moore is going to be published!

by | Sep 6, 2013 | , | 0 Comments

HNF’s CSO (Chief Scientific Officer), Sean Ekins wrote a blog about his work with Allison Moore and her two “fighter Mom” friends Lori Sames and Jill Wood. He named his blog: “Rare disease heroes – Extraordinary collaborators we should be listening too.” Sean helped my friends and I write a paper called: “Multifaceted roles of ultra rare and rare disease patients/parents in drug discovery.” YES, Allison Moore is going to be published! It will be in Drug Discovery Today, soon. The link to the reprint is below.

Join the conversation

Leave a Comment

0 Comments

Submit a Comment

Your email address will not be published. Required fields are marked *

Newsletter

Join for notifications on events, campaigns, & news